Wells Fargo & Company Reneo Pharmaceuticals, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RPHM
# of Institutions
67Shares Held
29.3MCall Options Held
51.7KPut Options Held
0-
Nea Management Company, LLC Timonium, MD4.79MShares$6.84 Million0.68% of portfolio
-
Tang Capital Management LLC San Diego, CA3MShares$4.28 Million0.55% of portfolio
-
Highbridge Capital Management LLC New York, NY2.92MShares$4.17 Million0.94% of portfolio
-
Carlyle Group Inc. Washington, DC2.7MShares$3.86 Million0.49% of portfolio
-
Bml Capital Management, LLC Zionsville, IN2.67MShares$3.82 Million2.88% of portfolio
About Reneo Pharmaceuticals, Inc.
- Ticker RPHM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,479,600
- Market Cap $35M
- Description
- Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...